GlaxoSmithKline launched its cervical cancer vaccine Cervarix in Britain on Tuesday, pricing it at the same level as Merck's rival Gardasil.
Both have a private prescription list price of 80 pounds ($163.4) per dose, or 240 pounds for a course of three shots.
Cervarix, which was approved by European authorities last week, is also on sale in Sweden and Germany. It won approval in Australia, its first major market, in May.
The two vaccines protect against cancer-causing strains of the sexually transmitted human papillomavirus (HPV) and are expected by analysts to be multibillion-dollars-a-year sellers.
More at Reuters
No comments:
Post a Comment